Skip to main content
. 2024 Oct 3;19(1):2408843. doi: 10.1080/15592294.2024.2408843

Figure 6.

Figure 6.

Time-to-viremia event analysis stratified by CMV serostatus risk group and CMV episcore.

(a) In the lung cohort (n = 77, 46 events), CMV episcore was associated with increased CMV viremia rates (HR 0.74, 95% CI 0.57–0.96, p* = 0.02). (b) Time to CMV viremia is shown for the renal transplant recipient cohort (n = 72, 18 events) shows no statistical difference with CMV episcore as a covariate but still it further frames the sero-risk intermediate group into 2 layers.